Karen Akinsanya

Karen Akinsanya

President, Head of Therapeutics R&D and Chief Strategy Officer, PartnershipsatSchrodinger· In proxies 2021–2025

Pay in FY2025-23% from the year before · Schrodinger stock -7.3% the same year

Karen Akinsanya was paid $2.1M in FY2025 (Dec), down 23%. Schrodinger stock fell 7.3% that year.

Pay$100 in the stock at the end of FY20 → $12
Pay is from the Summary Compensation Table of each Schrodinger proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. SchrodingerPublic company · 5 yr
    • President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships2021 – Present · 5 yrStock in role -63%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?